Parent satisfaction in a multi-site acute trial of risperidone in children with autism: A social validity study

Psychopharmacology

Volumn 191, Issue 1, 2007, Pages 149-157

  Tierney, Elaine ^a,b   Aman, Michael ^c   Stout, David ^a   Pappas, Krista ^c   Arnold, L Eugene ^c   Vitiello, Benedetto ^d   Scahill, Lawrence ^e   McDougle, Christopher ^f   McCracken, James ^g   Wheeler, Courtney ^a   Martin, Andres ^e   Posey, David ^f   Shah, Bhavik ^g  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism; Child; Clinical trial; Consumer satisfaction; Parent satisfaction; Risperidone

Indexed keywords

PLACEBO; RISPERIDONE;

ADOLESCENT; ARTICLE; AUTISM; CHILD; CONSUMER; CONTROLLED STUDY; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; ETHNIC GROUP; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; METHODOLOGY; PARENTAL ATTITUDE; PATIENT SATISFACTION; PERCEPTION; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION STUDY;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; CONSUMER SATISFACTION; DOUBLE-BLIND METHOD; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PARENTAL CONSENT; PARENTS; QUESTIONNAIRES; RESEARCH DESIGN; RISPERIDONE; TREATMENT OUTCOME; UNITED STATES;

EID: 33847167022     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0604-z     Document Type: Article

References (31)

1. Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491
2. Aman MG, Wolford PL (1995) Consumer satisfaction with involvement in drug research: a social validity study. J Am Acad Child Adolesc Psych 34:940-945
3. APA (American Psychiatric Association) (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington, DC
4. Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle CJ, McGough JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F (2000) Assessment in multisite randomized clinical trials (RCTs) of patients with autistic disorder: the autism RUPP network. J Autism Dev Disord 30:99-111
5. Baer DM, Wolf MM, Risley TD (1987) Some still-current dimensions of applied behavior analysis. Behavior Anal 20:313-327
6. Biederman J, Lopez FA, Boellner SW, Chandler MC (2002) A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110(2 Pt 1):258-66
7. Bukstein OG (2004) Satisfaction with treatment for attention-deficit/ hyperactivity disorder. Am J Manag Care 10:S107-S116
8. Derivan AT, Leventhal BL, March J, Wolraich M, Zito JM (2004) The ethical use of placebo in clinical trials involving children. J Child Adolesc Psychopharmacol 14:169-174
9. Dirkson SJ, D'Imperio JM, Birdsall D, Hatch SJ (2002) A postmarketing clinical experience study of metadate CD. Curr Med Res Opin 18:371-380
10. Frank E, Novick DM, Kupfer DJ (2003) Beyond the question of placebo control: ethical issues in psychopharmacological drug trials. I. Psychopharmacology 171:19-26
11. Gilbert DL, Buncher CR (2005) Assessment of scientific and ethical issues in two randomized clinical trial designs for patients with Tourette's syndrome: a model for studies of multiple neuropsychiatric diagnoses. J Neuropsychiatry Clin Neurosci 17(3):324-32
12. Guy W (1976) Clinical global impressions scale. ECDEU assessment: manual for psychopharmacology (revised edition). US Dept of Health, Education & Welfare. US Dept of Health, Education & Welfare publication (ADM 76-338), Rockville, MD, pp 217-222
13. Johnston C, Fine S (1993) Methods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: acceptability, satisfaction, and compliance. J Pediatr Psychol 18:717-730
14. Kazdin AE (1977) Assessing the clinical or applied importance of behavior change through social validation. Behav Modif 1:427-452
15. Lord C, Rutter M, Le Couteur A (1994) Autism diagnostic interview - revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24(5):659-685
16. McAdam DB, Zarcone JR, Hellings J, Napolitano DA, Schroeder SR (2002) Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. social validity measures. AAMR 107:261-269
17. McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ, Martin A, McGough JJ, Cronin P, Posey DJ, Riddle MA, Ritz L, Swiezy NB, Vitiello B, Volkmar FR, Votolato NA, Walson P (2000) Research units on pediatric psychopharmacology (RUPP)-autism network: background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 9(1):201-224
18. MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086
19. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabino GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD (2001) Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107(6):E105
20. Poling A, LeSage M (1995) Evaluating psychotropic drugs in people with mental retardation: Where are the social validity data? Am J Ment Retard 100:193-200
21. Research Units on Pediatric Psychopharmacology and Autism Network (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321
22. Roberts LW, Krystal J (2003) A time of promise, a time of promises: ethical issues in advancing psychopharmacological research. Psychopharmacology 17:1-5
23. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF (1997) Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36(6):844-852
24. Scahill L, McCracken JT, McDougle CJ, Aman MG, Arnold LE, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey DJ, Swiezy N, Volkmar F, Ritz L, Vitiello B (2001) Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 11(4):377-388
25. Scahill L, McDougle CJ, William SK, Dimitropoulos A, Aman MG, McCracken J, Tierney E, Arnold LE, Cronin P, Grados M, Ghuman J, Koenig K, Langworthy-Lam K, McGough J, Posey DJ, Ritz L, Swiezy NB, Vitiello B (2006) The children's Yale-Brown obsessive compulsive scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psych 45:1114
26. Vitiello B (2003) Ethical considerations in psychopharmacological research involving children and adolescents. Psychopharmacology 171:86-91
27. Vitiello B, Aman MG, Scahill L, McCracken JT, McDougle CJ, Tierney E, Davies M, Arnold LE (2005) Research knowledge among parents of children participating in a randomized clinical trial. J Am Acad Child Adolesc Psych 44:145-149
28. Wan GJ, Bukstein O (2003) Satisfaction with once-daily OROS methylphenidate in children and adolescents with ADHD. Poster presented at 16th US Psychiatric Mental Health Congress, Orlando, Florida, November 6-9
29. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M (2003) ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psych 42(4):424-433
30. Wolf MM (1978) The case for subjective measurement, or how behavior analysis is finding its heart. J Appl Behav Anal 11:203-214
31. Wolraich ML, Greenhill LL, Pelham WE, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G (2001) Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 108(4):883-892